The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comprehensive mutation analysis in NRG Oncology/RTOG 9802: A phase III study of RT vs RT + PCV in high-risk low-grade gliomas (LGGs).
 
Erica Hlavin Bell
Patents, Royalties, Other Intellectual Property - MIRNA-BASED PREDICTIVE MODELS FOR DIAGNOSIS AND PROGNOSIS OF PROSTATE CANCER Patent Pending; REVISED RECURSIVE PARTITIONING ANALYSIS (RPA) MODEL FOR GLIOBLASTOMA PATENT PENDING
 
Joseph P McElroy
No Relationships to Disclose
 
Jessica Fleming
No Relationships to Disclose
 
Cynthia Dawn Timmers
Stock and Other Ownership Interests - ARIAD; Array BioPharma; Seagen
 
Arup R Chakraborty
No Relationships to Disclose
 
Andrea L Salavaggione
No Relationships to Disclose
 
Edward G. Shaw
No Relationships to Disclose
 
Kenneth D. Aldape
Consulting or Advisory Role - Celldex
 
David Brachman
Stock and Other Ownership Interests - GammaTile
Patents, Royalties, Other Intellectual Property - Gammatile, LLC
Other Relationship - GammaTile
 
Albert D Murtha
No Relationships to Disclose
 
Minhee Won
No Relationships to Disclose
 
Minesh P. Mehta
Leadership - Pharmacyclics
Stock and Other Ownership Interests - Pharmacyclics
Honoraria - Ca Progress; Elekta; EMD Serono; Research to Practice
Consulting or Advisory Role - Bristol-Myers Squibb; Cavion; Celldex; Elekta; Novartis; Novocure; Roche/Genentech
Research Funding - Novelos (Inst); Novocure (Inst)
Other Relationship - Monteris Medical
 
Arnab Chakravarti
Patents, Royalties, Other Intellectual Property - Correlation of molecular markers with clinical outcome in GBM patients treated with and without Gefitinib; MIRNA-BASED PREDICTIVE MODELS FOR DIAGNOSIS AND PROGNOSIS OF PROSTATE CANCER; REVISED RECURSIVE PARTITIONING ANALYSIS (RPA) MODEL FOR GLIOBLASTOMA